MAPT and Alzheimer disease: In subpopulation 1, all AD subjects with positive amyloid and tau biomarkers (n = 135; A+T+) and SCD subjects without evidence for AD, thus with negative amyloid and tau biomarkers (n = 97; A−T−), were selected.